Yawen Wang

4PUBLICATIONS
3CO-AUTHORS
Medical infection agents (incl. prions)Predictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Apr 27, 2024
The role of proliferating stem-like plasma cells in relapsed or refractory multiple myeloma: Insights from single-cell RNA sequencing and proteomic analysis.

Jiadai Xu, Panpan Li, Yawen Wang

|Jan 27, 2023
The prognostic role of 1q21 gain/amplification in newly diagnosed multiple myeloma: The faster, the worse.

Yawen Wang, Jiadai Xu, Bei Xu

|Feb 16, 2022
Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial.

Yawen Wang, Mingzhi Zhang, Wei Song

|Feb 15, 2022
Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B-Cell lymphoma -results of a single center, retrospective cohort in China.

Yawen Wang, Hongwei Xue, Wei Song

Pageof 1

Frequent Collaborators

2 joint publications

Peng Liu

1 joint publications

Qingqing Cai

1 joint publications

Panpan Li